Antonio Passaro
Impact in
- Oncology top 0.5%
- Cancer Immunotherapy and Biomarkers
- COVID-19 and healthcare impacts
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- Pulmonary and Respiratory Medicine top 0.5%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
Papers in
-
- Lung Cancer Treatments and Mutations 116
- Lung Cancer Diagnosis and Treatment 30
- Gastric Cancer Management and Outcomes 9
- Oncology 86
- Lung Cancer Research Studies 30
- Cancer Immunotherapy and Biomarkers 25
- Colorectal Cancer Treatments and Studies 22
- Co-authors
- Solange Peters (14 shared papers)Tony S.K. Mok (10 shared papers)Filippo de Marinis (84 shared papers)Pasi Antero Janne (5 shared papers)Ilaria Attili (41 shared papers)David Planchard (5 shared papers)Jessica Menis (6 shared papers)Keith M. Kerr (3 shared papers)
- Journals
- Annals of Oncology (17 papers)ESMO Open (9 papers)Journal of Clinical Oncology (8 papers)Journal of Thoracic Oncology (8 papers)Clinical Lung Cancer (7 papers)
- Partner nations
- ItalyUnited StatesSwitzerland
In The Last Decade
Antonio Passaro
154 papers receiving 6.8k citations
Antonio Passaro's Hit Papers
Peers
Comparison fields: 5 of 121
- Oncology 3.2k
- Pulmonary and Respiratory Medicine 3.2k
- Cancer Research 837
- Molecular Biology 1.2k
- Radiology, Nuclear Medicine and Imaging 363
Countries citing papers authored by Antonio Passaro
This map shows the geographic impact of Antonio Passaro's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Antonio Passaro with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Antonio Passaro more than expected).
Fields of papers citing papers by Antonio Passaro
This network shows the impact of papers produced by Antonio Passaro. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Antonio Passaro. The network helps show where Antonio Passaro may publish in the future.
Co-authors
The 25 scholars most cited alongside Antonio Passaro, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 161 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up Hit paper breakdown → | 2023 | 558 |
| 2 | COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study Hit paper breakdown → | 2020 | 484 |
| 3 | Overcoming therapy resistance in EGFR-mutant lung cancer Hit paper breakdown → | 2021 | 411 |
| 4 | Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up Hit paper breakdown → | 2023 | 403 |
| 5 | Cancer biomarkers: Emerging trends and clinical implications for personalized treatment Hit paper breakdown → | 2024 | 366 |
| 6 | Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study Hit paper breakdown → | 2023 | 292 |
| 7 | Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC Hit paper breakdown → | 2024 | 250 |
| 8 | 2020 | 227 | |
| 9 | Managing Resistance to Immune Checkpoint Inhibitors in Lung Cancer: Treatment and Novel Strategies Hit paper breakdown → | 2022 | 222 |
| 10 | 2017 | 192 | |
| 11 | 2020 | 177 | |
| 12 | 2014 | 169 | |
| 13 | 2020 | 155 | |
| 14 | ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer Hit paper breakdown → | 2022 | 144 |
| 15 | 2019 | 131 | |
| 16 | 2020 | 109 | |
| 17 | 2021 | 98 | |
| 18 | Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study Hit paper breakdown → | 2024 | 85 |
| 19 | 2019 | 84 | |
| 20 | 2021 | 84 |
About Antonio Passaro
Antonio Passaro is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Cancer Research, Radiology, Nuclear Medicine and Imaging and Molecular Biology, having authored 161 papers that have together received 6.9k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (116 papers), Lung Cancer Research Studies (30 papers), Lung Cancer Diagnosis and Treatment (30 papers), Cancer Immunotherapy and Biomarkers (25 papers), Colorectal Cancer Treatments and Studies (22 papers), Cancer Genomics and Diagnostics (21 papers), Cancer therapeutics and mechanisms (13 papers) and Gastric Cancer Management and Outcomes (9 papers). The work is most often cited by research in Oncology (3.2k citations), Pulmonary and Respiratory Medicine (3.2k citations), Cancer Research (837 citations), Molecular Biology (1.2k citations) and Radiology, Nuclear Medicine and Imaging (363 citations). Antonio Passaro has collaborated with scholars based in Italy, United States and Switzerland. Frequent co-authors include Solange Peters, Tony S.K. Mok, Filippo de Marinis, Pasi Antero Janne, Ilaria Attili, David Planchard, Jessica Menis, Keith M. Kerr, Egbert Frederik Smit and Ursula Nestle. Their work appears in journals such as Annals of Oncology, ESMO Open, Journal of Clinical Oncology, Journal of Thoracic Oncology and Clinical Lung Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.